Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 733 to 744 of 756 entries
Sorted by: Best Match Show Resources per page
Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma.

Cancer research and treatment

Kim DY, Nam J, Chung JS, Kim SW, Shin HJ.
PMID: 33940789
Cancer Res Treat. 2022 Jan;54(1):301-313. doi: 10.4143/crt.2020.1371. Epub 2021 Apr 27.

PURPOSE: There are unmet needs associated with the current treatment strategies for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) due to the poor treatment outcomes of these strategies. Roflumilast, a selective phosphodiesterase-4 inhibitor used for treating chronic obstructive pulmonary disease,...

Cite
Kim DY, Nam J, Chung JS, et al. Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma. Cancer Res Treat. 2021;54(1):301-313doi: 10.4143/crt.2020.1371.
Kim, D. Y., Nam, J., Chung, J. S., Kim, S. W., & Shin, H. J. (2022). Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma. Cancer research and treatment, 54(1), 301-313. https://doi.org/10.4143/crt.2020.1371
Kim, Do Young, et al. "Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma." Cancer research and treatment vol. 54,1 (2022): 301-313. doi: https://doi.org/10.4143/crt.2020.1371
Kim DY, Nam J, Chung JS, Kim SW, Shin HJ. Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma. Cancer Res Treat. 2022 Jan;54(1):301-313. doi: 10.4143/crt.2020.1371. Epub 2021 Apr 27. PMID: 33940789.
Copy Download .nbib Format: NLM
Folate functionalized chitosan nanoparticles as targeted delivery systems for improved anticancer efficiency of cytarabine in MCF-7 human breast cancer cell lines.

International journal of biological macromolecules

Geethakumari D, Bhaskaran Sathyabhama A, Raji Sathyan K, Mohandas D, Somasekharan JV, Thavarool Puthiyedathu S.
PMID: 34973988
Int J Biol Macromol. 2021 Dec 30;199:150-161. doi: 10.1016/j.ijbiomac.2021.12.070. Epub 2021 Dec 30.

Anticancer drug cytarabine, has been widely used for treating haematological malignancies while it has minimal activity against solid tumours, which demands continuous infusion leading to high dose cytarabine toxicity. In this study, folate conjugated chitosan nanoparticles (FCCNP) were used...

Cite
Geethakumari D, Bhaskaran Sathyabhama A, Raji Sathyan K, et al. Folate functionalized chitosan nanoparticles as targeted delivery systems for improved anticancer efficiency of cytarabine in MCF-7 human breast cancer cell lines. Int J Biol Macromol. 2021;199:150-161doi: 10.1016/j.ijbiomac.2021.12.070.
Geethakumari, D., Bhaskaran Sathyabhama, A., Raji Sathyan, K., Mohandas, D., Somasekharan, J. V., & Thavarool Puthiyedathu, S. (2021). Folate functionalized chitosan nanoparticles as targeted delivery systems for improved anticancer efficiency of cytarabine in MCF-7 human breast cancer cell lines. International journal of biological macromolecules, 199150-161. https://doi.org/10.1016/j.ijbiomac.2021.12.070
Geethakumari, Deepa, et al. "Folate functionalized chitosan nanoparticles as targeted delivery systems for improved anticancer efficiency of cytarabine in MCF-7 human breast cancer cell lines." International journal of biological macromolecules vol. 199 (2021): 150-161. doi: https://doi.org/10.1016/j.ijbiomac.2021.12.070
Geethakumari D, Bhaskaran Sathyabhama A, Raji Sathyan K, Mohandas D, Somasekharan JV, Thavarool Puthiyedathu S. Folate functionalized chitosan nanoparticles as targeted delivery systems for improved anticancer efficiency of cytarabine in MCF-7 human breast cancer cell lines. Int J Biol Macromol. 2021 Dec 30;199:150-161. doi: 10.1016/j.ijbiomac.2021.12.070. Epub 2021 Dec 30. PMID: 34973988.
Copy Download .nbib Format: NLM
Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation.

Bone marrow transplantation

Zucenka A, Vaitekenaite V, Maneikis K, Davainis L, Pileckyte R, Trociukas I, Peceliunas V, Zvirblis T, Staras V, Griskevicius L.
PMID: 34274954
Bone Marrow Transplant. 2021 Nov;56(11):2804-2812. doi: 10.1038/s41409-021-01416-5. Epub 2021 Jul 17.

We retrospectively compared the outcomes of 20 patients receiving Venetoclax + low-dose Cytarabine + Actinomycin D (ACTIVE) with 29 patients receiving FLAG-Ida as salvage therapy for relapsed or refractory AML (R/R AML) after alloSCT. The groups were statistically balanced...

Cite
Zucenka A, Vaitekenaite V, Maneikis K, et al. Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant. 2021;56(11):2804-2812doi: 10.1038/s41409-021-01416-5.
Zucenka, A., Vaitekenaite, V., Maneikis, K., Davainis, L., Pileckyte, R., Trociukas, I., Peceliunas, V., Zvirblis, T., Staras, V., & Griskevicius, L. (2021). Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation. Bone marrow transplantation, 56(11), 2804-2812. https://doi.org/10.1038/s41409-021-01416-5
Zucenka, Andrius, et al. "Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation." Bone marrow transplantation vol. 56,11 (2021): 2804-2812. doi: https://doi.org/10.1038/s41409-021-01416-5
Zucenka A, Vaitekenaite V, Maneikis K, Davainis L, Pileckyte R, Trociukas I, Peceliunas V, Zvirblis T, Staras V, Griskevicius L. Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant. 2021 Nov;56(11):2804-2812. doi: 10.1038/s41409-021-01416-5. Epub 2021 Jul 17. PMID: 34274954.
Copy Download .nbib Format: NLM
Improved Survival of Leukemic Mice Treated with Sodium Caseinate in Combination with Daunorubicin without Toxicity.

Journal of oncology

Aguiñiga-Sánchez I, Meléndez-Ibarra FM, Ledesma-Martínez E, Weiss-Steider B, Fajardo-Orduña GR, Rangel-Corona R, García-Gervasio SN, Ramírez-Padilla MG, Lara-Castañeda JL, Santiago-Osorio E.
PMID: 33727925
J Oncol. 2021 Feb 27;2021:6635650. doi: 10.1155/2021/6635650. eCollection 2021.

In recent years, low doses of chemotherapy have been resumed and explored for the treatment of acute myeloid leukemia. Thus, CPX-351, a dual-drug liposomal encapsulation of cytarabine and daunorubicin, was approved by the US Food and Drug Administration, to...

Cite
Aguiñiga-Sánchez I, Meléndez-Ibarra FM, Ledesma-Martínez E, et al. Improved Survival of Leukemic Mice Treated with Sodium Caseinate in Combination with Daunorubicin without Toxicity. J Oncol. 2021;2021:6635650doi: 10.1155/2021/6635650.
Aguiñiga-Sánchez, I., Meléndez-Ibarra, F. M., Ledesma-Martínez, E., Weiss-Steider, B., Fajardo-Orduña, G. R., Rangel-Corona, R., García-Gervasio, S. N., Ramírez-Padilla, M. G., Lara-Castañeda, J. L., & Santiago-Osorio, E. (2021). Improved Survival of Leukemic Mice Treated with Sodium Caseinate in Combination with Daunorubicin without Toxicity. Journal of oncology, 20216635650. https://doi.org/10.1155/2021/6635650
Aguiñiga-Sánchez, Itzen, et al. "Improved Survival of Leukemic Mice Treated with Sodium Caseinate in Combination with Daunorubicin without Toxicity." Journal of oncology vol. 2021 (2021): 6635650. doi: https://doi.org/10.1155/2021/6635650
Aguiñiga-Sánchez I, Meléndez-Ibarra FM, Ledesma-Martínez E, Weiss-Steider B, Fajardo-Orduña GR, Rangel-Corona R, García-Gervasio SN, Ramírez-Padilla MG, Lara-Castañeda JL, Santiago-Osorio E. Improved Survival of Leukemic Mice Treated with Sodium Caseinate in Combination with Daunorubicin without Toxicity. J Oncol. 2021 Feb 27;2021:6635650. doi: 10.1155/2021/6635650. eCollection 2021. PMID: 33727925; PMCID: PMC7937462.
Copy Download .nbib Format: NLM
Efficacy and Safety of Azacytidine in Combination With Fludarabine and High-Dose Cytarabine With G-CSF (FLAG) in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.

Clinical lymphoma, myeloma & leukemia

Motabi IH, Aoun SMA, Al-Ammari M, Albtoosh BM, Iqbal S, Altaf SY, Tailor IK, Alnoamani MS, AlGhamdi MS, Zaidi SZ, AlShehry NF, Marei MA, Alfayez M.
PMID: 34417161
Clin Lymphoma Myeloma Leuk. 2021 Oct;21(10):720-723. doi: 10.1016/j.clml.2021.07.019. Epub 2021 Jul 29.

No abstract available.

Cite
Motabi IH, Aoun SMA, Al-Ammari M, et al. Efficacy and Safety of Azacytidine in Combination With Fludarabine and High-Dose Cytarabine With G-CSF (FLAG) in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Clin Lymphoma Myeloma Leuk. 2021;21(10):720-723doi: 10.1016/j.clml.2021.07.019.
Motabi, I. H., Aoun, S. M. A., Al-Ammari, M., Albtoosh, B. M., Iqbal, S., Altaf, S. Y., Tailor, I. K., Alnoamani, M. S., AlGhamdi, M. S., Zaidi, S. Z., AlShehry, N. F., Marei, M. A., & Alfayez, M. (2021). Efficacy and Safety of Azacytidine in Combination With Fludarabine and High-Dose Cytarabine With G-CSF (FLAG) in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Clinical lymphoma, myeloma & leukemia, 21(10), 720-723. https://doi.org/10.1016/j.clml.2021.07.019
Motabi, Ibraheem H, et al. "Efficacy and Safety of Azacytidine in Combination With Fludarabine and High-Dose Cytarabine With G-CSF (FLAG) in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study." Clinical lymphoma, myeloma & leukemia vol. 21,10 (2021): 720-723. doi: https://doi.org/10.1016/j.clml.2021.07.019
Motabi IH, Aoun SMA, Al-Ammari M, Albtoosh BM, Iqbal S, Altaf SY, Tailor IK, Alnoamani MS, AlGhamdi MS, Zaidi SZ, AlShehry NF, Marei MA, Alfayez M. Efficacy and Safety of Azacytidine in Combination With Fludarabine and High-Dose Cytarabine With G-CSF (FLAG) in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Clin Lymphoma Myeloma Leuk. 2021 Oct;21(10):720-723. doi: 10.1016/j.clml.2021.07.019. Epub 2021 Jul 29. PMID: 34417161.
Copy Download .nbib Format: NLM
A Dose-Response Relationship to Radiotherapy for Cutaneous Lesions of Langerhans Cell Histiocytosis.

Case reports in oncological medicine

Farrugia MK, Morrison C, Hernandez-Ilizaliturri F, Aljabab S.
PMID: 33833885
Case Rep Oncol Med. 2021 Mar 24;2021:6680635. doi: 10.1155/2021/6680635. eCollection 2021.

Langerhans cell histiocytosis (LCH) is a rare disease, afflicting approximately 4.6 and 1-2 per 1 million children and adults, respectively. While LCH can involve numerous organ systems such as the lung or bone, it is uncommon for the disease...

Cite
Farrugia MK, Morrison C, Hernandez-Ilizaliturri F, et al. A Dose-Response Relationship to Radiotherapy for Cutaneous Lesions of Langerhans Cell Histiocytosis. Case Rep Oncol Med. 2021;2021:6680635doi: 10.1155/2021/6680635.
Farrugia, M. K., Morrison, C., Hernandez-Ilizaliturri, F., & Aljabab, S. (2021). A Dose-Response Relationship to Radiotherapy for Cutaneous Lesions of Langerhans Cell Histiocytosis. Case reports in oncological medicine, 20216680635. https://doi.org/10.1155/2021/6680635
Farrugia, Mark K, et al. "A Dose-Response Relationship to Radiotherapy for Cutaneous Lesions of Langerhans Cell Histiocytosis." Case reports in oncological medicine vol. 2021 (2021): 6680635. doi: https://doi.org/10.1155/2021/6680635
Farrugia MK, Morrison C, Hernandez-Ilizaliturri F, Aljabab S. A Dose-Response Relationship to Radiotherapy for Cutaneous Lesions of Langerhans Cell Histiocytosis. Case Rep Oncol Med. 2021 Mar 24;2021:6680635. doi: 10.1155/2021/6680635. eCollection 2021. PMID: 33833885; PMCID: PMC8016594.
Copy Download .nbib Format: NLM
Primary mesenchymal stromal cells in co-culture with leukaemic HL-60 cells are sensitised to cytarabine-induced genotoxicity, while leukaemic cells are protected.

Mutagenesis

Gynn LE, Anderson E, Robinson G, Wexler SA, Upstill-Goddard G, Cox C, May JE.
PMID: 34505878
Mutagenesis. 2021 Nov 29;36(6):419-428. doi: 10.1093/mutage/geab033.

Tumour microenvironments are hallmarked in many cancer types. In haematological malignancies, bone marrow (BM) mesenchymal stromal cells (MSC) protect malignant cells from drug-induced cytotoxicity. However, less is known about malignant impact on supportive stroma. Notably, it is unknown whether...

Cite
Gynn LE, Anderson E, Robinson G, et al. Primary mesenchymal stromal cells in co-culture with leukaemic HL-60 cells are sensitised to cytarabine-induced genotoxicity, while leukaemic cells are protected. Mutagenesis. 2021;36(6):419-428doi: 10.1093/mutage/geab033.
Gynn, L. E., Anderson, E., Robinson, G., Wexler, S. A., Upstill-Goddard, G., Cox, C., & May, J. E. (2021). Primary mesenchymal stromal cells in co-culture with leukaemic HL-60 cells are sensitised to cytarabine-induced genotoxicity, while leukaemic cells are protected. Mutagenesis, 36(6), 419-428. https://doi.org/10.1093/mutage/geab033
Gynn, Liana E, et al. "Primary mesenchymal stromal cells in co-culture with leukaemic HL-60 cells are sensitised to cytarabine-induced genotoxicity, while leukaemic cells are protected." Mutagenesis vol. 36,6 (2021): 419-428. doi: https://doi.org/10.1093/mutage/geab033
Gynn LE, Anderson E, Robinson G, Wexler SA, Upstill-Goddard G, Cox C, May JE. Primary mesenchymal stromal cells in co-culture with leukaemic HL-60 cells are sensitised to cytarabine-induced genotoxicity, while leukaemic cells are protected. Mutagenesis. 2021 Nov 29;36(6):419-428. doi: 10.1093/mutage/geab033. PMID: 34505878; PMCID: PMC8633936.
Copy Download .nbib Format: NLM
Comparison in safety of chemotherapy protocols for blood cancers: toxicity of H-CVAD versus GELA/BURKIMAB/PETHEMA LAL.

Ecancermedicalscience

Marín-Sánchez A, Martínez-Fernández G, Gómez-Catalán I, Montoya-Morcillo MC, Algarra JL, García ÁI, Hernández-Fernández F, Romero-Macías JR.
PMID: 33912231
Ecancermedicalscience. 2021 Mar 22;15:1206. doi: 10.3332/ecancer.2021.1206. eCollection 2021.

BACKGROUND AND OBJECTIVE: The Hyper-CVAD/Methotrexate-Cytarabine (H-CVAD/MTX-AraC) chemotherapy protocol has been one of the standard treatments for blood cancers, such as Mantle cell lymphoma (MCL), Burkitt's lymphoma (BL) and B-cell and T-cell acute lymphoblastic leukaemia (ALL). Due to high toxicity,...

Cite
Marín-Sánchez A, Martínez-Fernández G, Gómez-Catalán I, et al. Comparison in safety of chemotherapy protocols for blood cancers: toxicity of H-CVAD versus GELA/BURKIMAB/PETHEMA LAL. Ecancermedicalscience. 2021;15:1206doi: 10.3332/ecancer.2021.1206.
Marín-Sánchez, A., Martínez-Fernández, G., Gómez-Catalán, I., Montoya-Morcillo, M. C., Algarra, J. L., García, �. �. I., Hernández-Fernández, F., & Romero-Macías, J. R. (2021). Comparison in safety of chemotherapy protocols for blood cancers: toxicity of H-CVAD versus GELA/BURKIMAB/PETHEMA LAL. Ecancermedicalscience, 151206. https://doi.org/10.3332/ecancer.2021.1206
Marín-Sánchez, Alberto, et al. "Comparison in safety of chemotherapy protocols for blood cancers: toxicity of H-CVAD versus GELA/BURKIMAB/PETHEMA LAL." Ecancermedicalscience vol. 15 (2021): 1206. doi: https://doi.org/10.3332/ecancer.2021.1206
Marín-Sánchez A, Martínez-Fernández G, Gómez-Catalán I, Montoya-Morcillo MC, Algarra JL, García ÁI, Hernández-Fernández F, Romero-Macías JR. Comparison in safety of chemotherapy protocols for blood cancers: toxicity of H-CVAD versus GELA/BURKIMAB/PETHEMA LAL. Ecancermedicalscience. 2021 Mar 22;15:1206. doi: 10.3332/ecancer.2021.1206. eCollection 2021. PMID: 33912231; PMCID: PMC8057780.
Copy Download .nbib Format: NLM
Successful treatment of multiple relapsed-refractory Langerhans cell histiocytosis with cyclosporine.

Tumori

Özyörük D, Yozgat AK, Kaçar D, Yazal Erdem A, Işık M, Güzelküçük Z, Hacısalihoğlu Ş.
PMID: 34423687
Tumori. 2021 Dec;107(6):NP120-NP122. doi: 10.1177/03008916211039555. Epub 2021 Aug 21.

Langerhans cell histiocytosis is a rare hematologic disorder and patients who fail first-line treatment have a poor prognosis, and require more intensive treatment. We present an infant diagnosed with multisystem Langerhans cell histiocytosis refractory to multimodal therapy who was...

Cite
Özyörük D, Yozgat AK, Kaçar D, et al. Successful treatment of multiple relapsed-refractory Langerhans cell histiocytosis with cyclosporine. Tumori. 2021;107(6):NP120-NP122doi: 10.1177/03008916211039555.
Özyörük, D., Yozgat, A. K., Kaçar, D., Yazal Erdem, A., Işık, M., Güzelküçük, Z., & Hacısalihoğlu, �. �. (2021). Successful treatment of multiple relapsed-refractory Langerhans cell histiocytosis with cyclosporine. Tumori, 107(6), NP120-NP122. https://doi.org/10.1177/03008916211039555
Özyörük, Derya, et al. "Successful treatment of multiple relapsed-refractory Langerhans cell histiocytosis with cyclosporine." Tumori vol. 107,6 (2021): NP120-NP122. doi: https://doi.org/10.1177/03008916211039555
Özyörük D, Yozgat AK, Kaçar D, Yazal Erdem A, Işık M, Güzelküçük Z, Hacısalihoğlu Ş. Successful treatment of multiple relapsed-refractory Langerhans cell histiocytosis with cyclosporine. Tumori. 2021 Dec;107(6):NP120-NP122. doi: 10.1177/03008916211039555. Epub 2021 Aug 21. PMID: 34423687.
Copy Download .nbib Format: NLM
Diffuse Alveolar Hemorrhage in the Setting of Cytarabine Therapy in a Critically Ill Patient.

Cureus

Phan AT, Hu J, Hasan M.
PMID: 34926047
Cureus. 2021 Nov 14;13(11):e19575. doi: 10.7759/cureus.19575. eCollection 2021 Nov.

Diffuse alveolar hemorrhage (DAH) is a potentially life-threatening pulmonary condition characterized by hypoxemia with progression to respiratory failure, rapid onset of dyspnea, and blood loss anemia. While hemoptysis may be present and corroborates the diagnosis, it is absent in...

Cite
Phan AT, Hu J, Hasan M. Diffuse Alveolar Hemorrhage in the Setting of Cytarabine Therapy in a Critically Ill Patient. Cureus. 2021;13(11):e19575doi: 10.7759/cureus.19575.
Phan, A. T., Hu, J., & Hasan, M. (2021). Diffuse Alveolar Hemorrhage in the Setting of Cytarabine Therapy in a Critically Ill Patient. Cureus, 13(11), e19575. https://doi.org/10.7759/cureus.19575
Phan, Alexander T, et al. "Diffuse Alveolar Hemorrhage in the Setting of Cytarabine Therapy in a Critically Ill Patient." Cureus vol. 13,11 (2021): e19575. doi: https://doi.org/10.7759/cureus.19575
Phan AT, Hu J, Hasan M. Diffuse Alveolar Hemorrhage in the Setting of Cytarabine Therapy in a Critically Ill Patient. Cureus. 2021 Nov 14;13(11):e19575. doi: 10.7759/cureus.19575. eCollection 2021 Nov. PMID: 34926047; PMCID: PMC8671050.
Copy Download .nbib Format: NLM
High dose cytarabine, mitoxantrone, pegasapargase (HAM-pegA) in combination with dasatinib for the first-line treatment of Philadelphia chromosome positive mixed phenotype acute leukemia.

American journal of leukemia research

Patzke CL, Emadi A.
PMID: 33283208
Am J Leuk Res. 2020;4(1). Epub 2020 Oct 15.

The treatment of mixed phenotype acute leukemia (MPAL) is challenging due to the presence of disease characteristics of both myeloid and lymphoid leukemia. Regimens historically used to treat acute lymphoblastic leukemia are often used to treat MPAL, particularly for...

Cite
Patzke CL, Emadi A. High dose cytarabine, mitoxantrone, pegasapargase (HAM-pegA) in combination with dasatinib for the first-line treatment of Philadelphia chromosome positive mixed phenotype acute leukemia. Am J Leuk Res. 2020;4(1)
Patzke, C. L., & Emadi, A. (2020). High dose cytarabine, mitoxantrone, pegasapargase (HAM-pegA) in combination with dasatinib for the first-line treatment of Philadelphia chromosome positive mixed phenotype acute leukemia. American journal of leukemia research, 4(1), .
Patzke, Ciera L, and Emadi, Ashkan. "High dose cytarabine, mitoxantrone, pegasapargase (HAM-pegA) in combination with dasatinib for the first-line treatment of Philadelphia chromosome positive mixed phenotype acute leukemia." American journal of leukemia research vol. 4,1 (2020).
Patzke CL, Emadi A. High dose cytarabine, mitoxantrone, pegasapargase (HAM-pegA) in combination with dasatinib for the first-line treatment of Philadelphia chromosome positive mixed phenotype acute leukemia. Am J Leuk Res. 2020;4(1). Epub 2020 Oct 15. PMID: 33283208; PMCID: PMC7717491.
Copy Download .nbib Format: NLM
Safety and feasibility of outpatient high-dose cytarabine and intermediate-dose cytarabine for consolidation therapy in acute myeloid leukemia.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Li W, Richter K, Lee J, McCarthy K, Kubal T.
PMID: 34609924
J Oncol Pharm Pract. 2021 Oct 05;10781552211046574. doi: 10.1177/10781552211046574. Epub 2021 Oct 05.

INTRODUCTION: The standard of care consolidation therapy for acute myeloid leukemia is high-dose cytarabine or intermediate-dose cytarabine, which are traditionally given inpatient. At Moffitt Cancer Center, we have moved the administration of high-dose cytarabine and intermediate-dose cytarabine to the...

Cite
Li W, Richter K, Lee J, et al. Safety and feasibility of outpatient high-dose cytarabine and intermediate-dose cytarabine for consolidation therapy in acute myeloid leukemia. J Oncol Pharm Pract. 2021;10781552211046574doi: 10.1177/10781552211046574.
Li, W., Richter, K., Lee, J., McCarthy, K., & Kubal, T. (2021). Safety and feasibility of outpatient high-dose cytarabine and intermediate-dose cytarabine for consolidation therapy in acute myeloid leukemia. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 10781552211046574. https://doi.org/10.1177/10781552211046574
Li, Wenhui, et al. "Safety and feasibility of outpatient high-dose cytarabine and intermediate-dose cytarabine for consolidation therapy in acute myeloid leukemia." Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners vol. (2021): 10781552211046574. doi: https://doi.org/10.1177/10781552211046574
Li W, Richter K, Lee J, McCarthy K, Kubal T. Safety and feasibility of outpatient high-dose cytarabine and intermediate-dose cytarabine for consolidation therapy in acute myeloid leukemia. J Oncol Pharm Pract. 2021 Oct 05;10781552211046574. doi: 10.1177/10781552211046574. Epub 2021 Oct 05. PMID: 34609924.
Copy Download .nbib Format: NLM
Showing 733 to 744 of 756 entries